UNSPSC 51322600: Antihyperlipidemic and hypocholesterolemic sulfur compounds

Antihyperlipidemic and hypocholesterolemic drugs inorganic or organic compounds that contain sulfur as an integral part of the molecule.

UNSPSC 51322600 Antihyperlipidemic and hypocholesterolemic sulfur compounds is a Class code under which state and local governments procure pharmaceutical products, though recent solicitation activity shows broader medication categories than the code name suggests. The City of Tampa's 2026 bid for Advanced Life Support Medications (Bid No. 26-P-00188) solicited critical-care injectables including Labetalol, Epinephrine, Adenosine, and Diltiazem for Tampa Fire Rescue rather than cholesterol-management compounds. Similarly, the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for Generic Multi Source Pharmaceuticals and OTC Products and the Texas Health and Human Services Commission's RFI on Direct-to-Manufacturer Prescriptions both reference broad pharmaceutical categories under this code classification. State and local purchasers under this code span municipal fire departments, state health and human services agencies, and multistate cooperative purchasing consortia. Issuing bodies include city purchasing departments (Tampa), state health authorities (Texas HHS Commission), and cooperative purchasing administrations (MMCAP, operated by the Minnesota Department of Administration).

The most recent activity clusters in Florida, Texas, and Minnesota. The Tampa IFB (response due April 8, 2026, estimated value $40,000) required sealed bids for four emergency medication line items with nine-month-minimum expiration dates and ten-day delivery, with a 5 percent bid discount for Small Local Business Enterprise participation capped at $10,000. The MMCAP RFP (response due March 26, 2026) established multi-contract awards for generic pharmaceuticals and OTC products effective July 1, 2026, through authorized wholesalers including AmerisourceBergen, Cardinal Health, and Morris & Dickson, requiring cGMP and Drug Supply Chain Security Act certification, $5,000,000 commercial general liability coverage, and pricing weighted 75 percent on competitiveness. The Texas RFI (April 3, 2026 deadline) sought preliminary market intelligence on direct-to-manufacturer prescription fulfillment without PBMs or GPOs, signaling future formal solicitation. None of the recent opportunities align closely with the code's stated focus on lipid-management sulfur compounds; procurement appears to use this classification broadly for pharmaceutical supply.